十月稻田、鍋圈、藥明合聯及中旭未來漲9%-17% 中金料有望納入港股通
恆指三連升,高低見16,200/15,937,現報16,174,升229點或1.4%,總成交額277億元。
大行估計有望納入港股通的部分股份今早跑贏大市。半新股中旭未來(09890.HK)連升第六天,最高見32.4元,現報30.9元,升17%。藥明合聯(02268.HK)止跌回升,曾高見14.56元,現報14.34元,回升逾10%。世茂(00813.HK)回升9.4%報0.46元,股價重越10天及20天線。
鍋圈(02517.HK)連升第二天兼重越10天及50天線,最高見8.54元,現報8.41元,續升9.2%。十月稻田(09676.HK)回升8.9%報22.75元。
友寶在線(02429.HK)重越20天線,最高見19.6元,現報19元,回升5.6%。科倫博泰生物-B(06990.HK)連升第四天,今早低開報85.7元獲承接,掉頭倒升6.2%報94.4元,股價重越50天線。萬物雲(02602.HK)高見19.3元,現報19.14元,續升4.7%。藍月亮(06993.HK)高見2.04元,現報1.99元,回升3.1%。
中金日前預計,24隻股票有望納入港股通,包括藥明合聯、山高(00412.HK)、東亞銀行(00023.HK)、藍月亮、中環新能源(01735.HK)、恆隆集團(00010.HK)、中旭未來、鍋圈、優必選(09880.HK)、友寶在線、萬物雲、世茂集團、粵豐環保(01381.HK) 、中國食品(00506.HK) 、科倫博泰生物、第四範式(06682.HK)、十月稻田、宜明昂科-B(01541.HK)、中國春來(01969.HK)、瑞浦蘭鈞(00666.HK)、君聖泰醫藥-B(02511.HK)、滄港鐵路(02169.HK)、神威藥業(02877.HK)和巨星傳奇(06683.HK)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.